Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

5.76
Delayed Data
As of Sep 23
 -0.07 / -1.20%
Today’s Change
4.45
Today|||52-Week Range
14.93
-30.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$758.8M

Company Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. It is focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.

Contact Information

ZIOPHARM Oncology, Inc.
Parris Building
Boston Massachusetts 02129
P:(617) 259-1970
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Laurence James Neil CooperChief Executive Officer & Managing Director
Caesar J. BelbelCOO, Secretary, Chief Legal Officer & Executive VP
Kevin G. LafondChief Financial Officer, Treasurer, CAO & VP
Francois LebelChief Medical Officer, EVP-Research & Development
Lynn M. FerrucciSVP-Human Resources, Facilities & Administration